Клініко-патогенетична роль імунозапальних порушень та ендотеліальної дисфункції у хворих на ішемічну хворобу серця, коморбідну з гіпотиреозом (огляд літератури)

N. S. Mykhailovska, T. V. Oliinyk, Y. M. Mykhailovskyi

Анотація


Представлені сучасні наукові дані щодо клініко-патогенетичної ролі маркерів імунного запалення та ендотеліальної дисфункції у хворих на ішемічну хворобу серця, коморбідну з гіпотиреозом. Обговорюються перспективи використання С-реактивного протеїну, фактора некрозу пухлини-α, неоптерину, ендотеліну як індикаторів ризику виникнення кардіоваскулярних подій при ішемічній хворобі серця в пацієнтів із гіпотиреозом у клінічній практиці.


Ключові слова


стабільна стенокардія напруження; гіпотиреоз; клінічний перебіг; імунозапальні порушення; ендотеліальна дисфункція

Повний текст:

PDF

Посилання


Alekperov EZ, Nadzhafov RN. Sovremennye kontseptsii o roli vospaleniya pri ateroskleroze [Modern concepts of the role of inflammation in atherosclerosis]. Kardiologiya. 2010;6:88-91. (in Russian).

Volkova AR, Dora SV, Badmaeva MI. Vyrazhennost' koronarnogo ateroskleroza u bol'nykh ishemicheskoy bolezn'yu serdtsa s razlichnym funktsional'nym sostoyaniem shchitovidnoy zhelezy [Severity of coronary atherosclerosis in patients with ischemic heart disease with various functional states of the thyroid gland]. Vestn. Sankt-Peterburgskogo un-ta. 2008;3:7-13. (in Russian).

Degtyareva OV, Petyunina OV. Syvorotochnyy neopterin i S-reaktivnyy belok u bol'nykh s raznymi klinicheskimi variantami ostrogo koronarnogo sindroma [Serum neopterin and C-reactive protein in patients with different clinical variants of acute coronary syndrome]. Ukr. terapevt. zh. 2008;1:41-4. (in Russian).

Zueva OM, Malakhova YuI. Vozrastnye i sezonnye kharakteristiki pokazateley gipofizarno-tireoidnoy, lipidotransportnoy i immunnoy sistem u zdorovykh muzhchin [Age and seasonal characteristics of pituitary-thyroid, lipid-transport and immune systems in healthy men]. Omsk. nauch. vestn. Ser. Resursy Zemli. Chelovek. 2012;2:113-16. (in Russian).

Dorzhieva LV, Kushkhova DKh, Orlova OV. Klinicheskoe i diagnosticheskoe znachenie urovnya neopterina u bol'nykh s ishemicheskoy bolezn'yu serdtsa [Clinical and diagnostic value of neopterin level in patients with coronary heart disease]. Kardiovaskulyarnaya terapiya i profilaktika. 2007;5:88-9. (in Russian).

Kopytsia MP, Hil'ova IaV, Bila NV. Zapalennia ta aterohenezu. Prohnostychne znachennia markera sudynnoho zapalennia liporotein-asotsiiovanoi fosfolipazy A2 pry hostromu koronarnomu syndromi [Inflammation and atherogenesis. Prognostic value of the marker of vascular inflammation of the lipotic-associated phospholipase A2 with acute coronary syndrome]. Visn. Kharkiv. nats. un-ta im. V.N. Karazina. 2012;998:65-71. (in Ukrainian).

Kravchenko VI, Postol SV. Dynamika zakhvoriuvanosti na patolohiiu schytopodibnoi zalozy v Ukraini [The dynamics of morbidity in pathology of thyroid gland in Ukraine]. Mezhdunar. endokrinol. zh. 2011;3:56-9. (in Ukrainian).

Marushko TV, Berezhnoi VV, Havrylenko TY. Rol' pro- i protyzapal'nykh tsytokiniv u rozvytku zapal'noho protsesu pry yuvenil'nomu revmatoidnomu artryti [The role of pro- and anti-inflammatory cytokines in the development of inflammatory process in juvenile rheumatoid arthritis]. Ukr. revmatol. zh. 2006;23:33-6. (in Ukrainian).

Mitchenko OI, Lohvynenko AO, Romanov Viu. Optymizatsiia likuvannia dyslipidemii ta porushen' vuhlevodnoho obminiv u khvorykh z metabolichnym syndromom ta dysfunktsiieiu schytopodibnoi zalozy [Optimization of treatment of dyslipidemia and carbohydrate metabolism disorders in patients with metabolic syndrome and thyroid dysfunction]. Ukr. kardiol. zh. 2010;1:73-80. (in Ukrainian).

Paleev FN, Abudeeva IS, Moskalets OV. Nespetsificheskie markery vospaleniya v prognozirovanii techeniya ishemicheskoy bolezni serdtsa [Nonspecific markers of inflammation in predicting the course of coronary heart disease]. Kardiologiya. 2009;9:59-65. (in Russian).

El'skiy VN, Vatutin NT, Kalinkina NV. Rol' disfunktsii endoteliya v geneze serdechno-sosudistykh zabolevaniy [The role of endothelial dysfunction in the genesis of cardiovascular diseases]. Zh. AMN Ukrainy. 2008;14(1):5-62. (in Russian).

Kopitsa NP, Litvin EI, Petyunina OV. Rol' neopterina v prognozirovanii serdechnoy nedostatochnosti u bol'nykh, perenesshikh infarkt miokarda [The role of neopterin in predicting heart failure in patients who underwent myocardial infarction]. Ukr. terapevt. zh. 2006;4:19-22. (in Russian).

Ruzhentsova UYu. Vzaimosvyaz' mezhdu simpaticheskoy nervnoy sistemoy i endotelinom-1 v kapillyarnom krovotoke u bol'nykh ishemicheskoy bolezn'yu serdtsa - znachenie GNB3 S825T polimorfizma [The relationship between the sympathetic nervous system and endothelin-1 in the capillary blood flow in patients with ischemic heart disease – value of GNB3 of the C825T polymorphism]. Lech. vrach. 2008;1:87-92. (in Russian).

Sviridov AE, Telegina TA. Neopterin i ego vosstanovlennye formy: biologicheskaya rol' i uchastie v kletochnom immunitete [Neopterin and its restored forms: a biological role and participation in the cellular immunity]. Usp. biol. khimii. 2005;45:355-90. (in Russian).

Vieira SM, Lemos HP, Grespan R. A crucial role for TNF-α in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5. Br. J. Pharmacol. 2009;158:779-89.

Calabro P, Golia E, Yeh TH. C-reactive protein and the risk of atherosclerosis events. Seminars in immunopathology. 2009;31:79-94.

Alessandris CD, Lauro R, Presta I. C-reactive protein induces phosphorylation of insulin receptor substrate–1 Ser (307) and Ser (612) in L6 myocytes, thereby impairing the insulinsignalling pathway that promotes glucose transport. Diabetologia. 2007;50(4):840-49.

Boekholdt SM, Hack CE, Sandhu MS. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis. 2006;187:415-22.

Inge Oever AM, Raterman HG, Nurmohamed MT. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm. 2010;15:79-93.

Nichols M, Townsend N, Scarborough P. European Cardiovascular Disease in Euroupe: epidemiological update. European Heart J. 2013;34:3028-034. Mode of access: http://dx.doi.org/10.1093/eurheartj/eht356.

Heron M. Death: Leading Causes for 2009. National Vital Statistics Reports. 2012;61(7):3-96.

Hueston WJ, King DE, Geesey ME. Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism. Clin. Endocrinol. (Oxf). 2005;63:582-87.

Lourenco P, Araujo JP, Paulo C. Higher C-reactive protein predicts worse prognosis in acute heart failure only in noninfected patients. Clin. Cardiol. 2010;33:708-14.

Nada S, Khazaei M, Laher I. Effect of moderate-intensity exercise on plasma c-reactive protein and aortic endothelial function in type 2 diabetic mice. Mediators Inflamm. 2010. Mode of access: http://dx.doi.org/10.1155/2010/149678.

Adachi T, Naruco T, Itoh A. Neopterin is associated with plaque inflammation and destabilization in human coronary atherosclerotic lesions. Heart. 2007;93:1537-541.

Nystrom T, Nygren A, Sjoholm A. Persistent endothelial dysfunction is related to elevated C-reactive protein levels in type II diabetic patients after acute myocardial infarction. Clin. Science. 2005;12:121-28.

Ridker PM, Silvertown JD. Inflammation, C-reactive protein, and atherothrombosis. J. of Periodontology. 2008;79:1544-551.

Saenger AK, Jaffe AS. The use of biomarkers for the evaluation and treatment of patients with acute coronary syndromes. Med. Clin. North. Am. 2007;91:657-81.

Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation. 2006;113:2128-134.

Silva D, Lacerda de AP. High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease. Revista Portuguesa de Cardiologia. 2012;31:733-45.

Tuzcu A, Bahceci M, Gokalp D. Subclinical hypothyroidism may be associated with eievated high-sensitive C-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Enddocr J. 2005;52:89-94.

Gencer B, Collet TH, Virgini V. Subclinical thyroid dysfunction and cardiovascular outcomes among prospective cohort studies. Endocr Metab Immune Disord Drug Targets. 2013;13:4-12.

Taddei S, Caraccio N, Virdis A. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab. 2003;88:3731-737.

Taddei S. New evidence for endothelial protection. Medicographia. 2012;34:17-24.

Valgimigli M. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA. 2005;293:2109-117.


Пристатейна бібліографія ГОСТ






DOI: https://doi.org/10.24061/110558

Посилання

  • Поки немає зовнішніх посилань.


Copyright (c) 2017 N. S. Mykhailovska, T. V. Oliinyk, Y. M. Mykhailovskyi

Технічний редактор журналу, к.мед.н. М. Степанченко, 2015-2017